Eclipse Clinical Research

1. Eli Lilly and Company $2,404,386 3 payments
2. Amgen Inc. $521,415 14 payments
3. Bayer HealthCare Pharmaceuticals Inc. $322,544 42 payments
4. Sanofi US Services Inc. $304,201 45 payments
5. AbbVie, Inc. $243,269 24 payments
6. Novartis Pharmaceuticals Corporation $220,673 15 payments
7. AstraZeneca Pharmaceuticals LP $165,763 24 payments
8. Kowa Research Institute, Inc. $159,485 35 payments
9. Merck Sharp & Dohme Corporation $96,131 7 payments
10. GlaxoSmithKline, LLC. $77,266 17 payments

1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $2,404,386 3 payments
2. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $485,982 1 payment
3. BAY1454032 Essure System for Permanent Birth Control $295,362 30 payments
4. M16-100 $237,149 19 payments
5. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $144,302 13 payments
6. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $125,350 7 payments
7. K-877-302 $107,396 18 payments
8. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $96,051 6 payments
9. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $83,264 9 payments
10. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $62,294 4 payments

1. Patient care $48,989 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.